Home › Diffuse Large B-Cell Lymphoma › Nevada › Las Vegas
Diffuse Large B-Cell Lymphoma clinical trials in Las Vegas, NV
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Las Vegas (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- OptumCare Cancer Care ( Site 0121), Las Vegas
- Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
- Comprehensive Cancer Centers of Nevada ( Site 0168), Las Vegas
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Comprehensive Cancer Centers of Nevada, Las Vegas
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY20 studies
- Baldwin Park, CA19 studies
- Los Angeles, CA18 studies
- Houston, TX18 studies
- Chicago, IL18 studies
- Milwaukee, WI17 studies
- Nashville, TN17 studies
- Boston, MA17 studies
- Philadelphia, PA15 studies
- Durham, NC15 studies
- Portland, OR15 studies
- Cleveland, OH13 studies
Other studies in Las Vegas
- Obesity21 studies
- Overweight19 studies
- Type 2 Diabetes17 studies
- Major Depressive Disorder13 studies
- Breast Cancer11 studies
- Non-Small Cell Lung Cancer10 studies
- Cancer (all types)9 studies
- Metastatic Cancer8 studies
- Colorectal Cancer8 studies
- Schizophrenia7 studies
- Prostate Cancer7 studies
- Alzheimer's Disease7 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.